Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat in chronic heart failure with reduced ejection fraction
NCT05093933Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 36
01
Overview
A Phase 3 trial of Vericiguat oral suspension (Formulation 4) in heart failure with reduced ejection fraction (HFrEF), sponsored by Merck & Co.. Started Nov 2021; status: completed.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT05093933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05093933.